SCHEMBL19950076

SCHEMBL19950076

Cc1cc(NC(=O)CCl)cc(Cl)c1-c1cc2c(-c3cnn(C)c3)nn(C(=O)O)c2cn1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
S1PR2 O95136 2/20 0.37
MAP4K1 Q92918 5/20 0.36
NTRK1 P04629 2/20 0.36
KIT P10721 2/20 0.36
FLT3 P36888 2/20 0.36
PIM1 P11309 1/20 0.32
LMNA P02545 1/20 0.32
CSF1R P07333 1/20 0.32
MAPK1 P28482 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
KDR P35968 2/20 0.32
CREBBP Q92793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950488 0.91 MAP4K1 (0.44) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19950429 0.91 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL29746695 0.89 TTK (0.39) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19950173 0.89 TTK (0.39) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19950315 0.87 ALDH1A1 (0.43) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19950602 0.87 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1S1PR2
SCHEMBL19950599 0.82 MAP4K1 (0.46) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP4K1
SCHEMBL19950023 0.81 MAP4K1 (0.40) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP4K1
SCHEMBL19949978 0.80 MAP4K1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP4K1
SCHEMBL19950714 0.80 MAP4K1 (0.38) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
EP-3510032-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER Incyte Corporation (US) 2019-07-17 EP disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.